Skip to main content

Horizon Therapeutics(HZNP-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low61.85
Day High64.16
Open:63.05
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Business Wire - Thu Sep 29, 7:00AM CDT
Business Wire
Thu Sep 29, 7:00AM CDT
Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score...
Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
Business Wire - Thu Sep 22, 7:04AM CDT
Business Wire
Thu Sep 22, 7:04AM CDT
Horizon Therapeutics plc (Nasdaq: HZNP) today expanded its commitment to education equity, science, technology, engineering, arts and math (STEAM) careers and historically Black colleges and universities (HBCUs) through its Horizon Scholars...
Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
Business Wire - Wed Sep 21, 7:04AM CDT
Business Wire
Wed Sep 21, 7:04AM CDT
Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce the winning solution of this year’s Horizon Prize: Patient-Driven Data Platform for Rare Disease by EB...

Latest Articles